The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer

The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer

BackgroundBorderline Resectable Pancreatic Cancer (BRPC) remains a unique entity that is difficult to categorize due to variance in definitions and the small number of patients. The ultimate goal is to achieve a free resection (R0) after a favorable response to neoadjuvant therapy that is somewhat d...

Full description

Bibliographic Details
Main Authors:	Nervana Hussien, Rasha S. Hussien, Darine Helmy Amin Saad, Mohamed El Kassas, Walid F. Elkhatib, Mai Ezz El Din
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Oncology
Subjects:	borderline resectable pancreatic cancer ADC radiological assessment RECIST criteria DWI-MRI
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.796317/full

Similar Items

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01)

Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
by: CHEN Zegang, et al.
Published: (2022-09-01)

Cutting‐edge strategies for borderline resectable pancreatic cancer
by: Rajesh S. Shinde, et al.
Published: (2019-07-01)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
by: Hyun Jeong Jeon, et al.
Published: (2023-08-01)

How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated—A Comprehensive Review
by: Daria Kwaśniewska, et al.
Published: (2023-08-01)

Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition
by: Louisa Bolm, et al.
Published: (2020-04-01)

Effect of region of interest size on ADC measurements in pancreatic adenocarcinoma
by: Chao Ma, et al.
Published: (2017-05-01)

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
by: Hye-Sol Jung, et al.
Published: (2022-09-01)

Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management
by: Fawaz A, et al.
Published: (2022-12-01)

Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
by: Marko Damm, et al.
Published: (2021-08-01)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
by: Marco Massani, et al.
Published: (2023-01-01)

Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study
by: Alexey Surov, et al.
Published: (2022-12-01)

Diagnostic performance of ADC value in histopathological grading of mass-forming cholangiocarcinoma
by: Heba Said Ellaban, et al.
Published: (2022-11-01)

Is high-intensity focused ultrasound (HIFU) an option for neoadjuvant therapy for borderline resectable pancreatic cancer patients? – a systematic review
by: Nadya Stanislavova, et al.
Published: (2021-09-01)

Role of DWI in evaluation of HCC after radiofrequency ablation compared to dynamic MRI using MRI (3 T)
by: Bahaa Mohamed Elrefaey Hasan, et al.
Published: (2021-11-01)

Diffusion-weighted MR imaging diagnostic merits in the post-therapeutic assessment of musculoskeletal soft tissue sarcoma
by: Amr Farouk Ibrahim Moustafa, et al.
Published: (2019-11-01)

Magnetic resonance apparent diffusion coefficient values of the brain in COPD
by: Mohammad El Desouky Abo Shehata, et al.
Published: (2017-04-01)

Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma—A Retrospective Studies of Nine Cases
by: Nicolae Bacalbasa, et al.
Published: (2021-07-01)

Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer
by: Nana Kimura, et al.
Published: (2020-12-01)

The role of combined diffusion weighted imaging and magnetic resonance cholangiopancreatography in the differential diagnosis of obstructive biliary disorders
by: Shaimaa Rabie, et al.
Published: (2021-05-01)

Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
by: Mitsuru Kinoshita, et al.
Published: (2022-09-01)

Apparent diffusion coefficient of pancreatic adenocarcinoma: is there any congruity with tumor resectability?
by: M. Abdel Kader, et al.
Published: (2019-09-01)

Diffusion-weighted MRI in liver fibrosis staging: Added value of normalized ADC using spleen and renal cortex as reference organs
by: Tamer F. Taha Ali, et al.
Published: (2017-03-01)

Prognostic Value of Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Carcinoma Followed by Pancreatectomy with Portal Vein Resection and Reconstruction with Venous Allograft
by: Jin-Can Huang, et al.
Published: (2022-12-01)

A single‐institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors
by: Raja Shaikh, et al.
Published: (2023-06-01)

DWI as a biomarker of renal function in children with CKD: what is the potential?
by: Sally Emad-Eldin, et al.
Published: (2020-08-01)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
by: Chenqi Wang, et al.
Published: (2022-06-01)

Automatic segmentation of hepatic metastases on DWI images based on a deep learning method: assessment of tumor treatment response according to the RECIST 1.1 criteria
by: Xiang Liu, et al.
Published: (2022-12-01)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors—A Systematic Review and Meta-Analysis
by: Hans-Jonas Meyer, et al.
Published: (2019-09-01)

Diffusion weighted MRI of mediastinal masses: Can measurement of ADC value help in the differentiation betw
by: A. Nasr, et al.
Published: (2016-03-01)

Role of dynamic contrast enhanced and diffusion weighted MRI in the differentiation between post treatment changes and recurrent laryngeal cancers
by: SalahEldin Desouky, et al.
Published: (2015-06-01)

Advances in Radiation Oncology for Pancreatic Cancer: An Updated Review
by: Jason Liu, et al.
Published: (2022-11-01)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
by: Changhoon Yoo, et al.
Published: (2019-02-01)

Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma
by: Iranzu González-Borja, et al.
Published: (2022-12-01)

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)
by: Ken‐ichi Okada, et al.
Published: (2023-11-01)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
by: Jin Ho Choi, et al.
Published: (2022-09-01)

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
by: Megan L. Sulciner, et al.
Published: (2022-08-01)

Differentiation of Benign and Malignant Breast Lesions Using ADC Values and ADC Ratio in Breast MRI
by: Silvia Tsvetkova, et al.
Published: (2022-01-01)

Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?
by: Rupaly Pandé, et al.
Published: (2019-10-01)